Change in HbA<sub>1c</sub> Across the Baseline HbA<sub>1c</sub> Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.

Gentilella, Raffaella; Romera, Irene; Nicolay, Claudia; Buzzetti, Raffaella; Vázquez, Luis Alberto; Sesti, Giorgio

Change in HbA_1c Across the Baseline HbA_1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.

Gentilella, Raffaella; Romera, Irene; Nicolay, Claudia; Buzzetti, Raffaella; Vázquez, Luis Alberto; Sesti, Giorgio.

Afiliação

Gentilella R; Eli Lilly Italia, Sesto Fiorentino, Florence, Italy.
Romera I; Eli Lilly and Company, Alcobendas, Madrid, Spain. romera_irene@lilly.com.
Nicolay C; Lilly Deutschland GmbH, Bad Homburg, Germany.
Buzzetti R; Department of Experimental Medicine "Sapienza", University of Rome, Rome, Italy.
Vázquez LA; Hospital Marqués de Valdecilla, Santander, Spain.
Sesti G; University Magna Graecia, Catanzaro, Italy.

Diabetes Ther ; 10(3): 1113-1125, 2019 Jun.

Article em En | MEDLINE | ID: mdl-31055780

Palavras-chave

Dulaglutide; HbA1c; Incretin-based therapy; Range metabolic control; Type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Diabetes Ther Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google